Arcutis Biotherapeutics initiates enrollment in INTEGUMENT-3 trial of ZORYVE for atopic dermatitis

Arcutis Biotherapeutics has initiated enrollment in its INTEGUMENT-3 trial evaluating ZORYVE to treat atopic dermatitis.

Detected & updated continuously · Source: Nebula